Attachment of a migrated MitraClip to the left ventricular apex: A novel case report

Nagai, Mirei; Kurokawa, Syuhei; Ozaki, Makoto; Nomura, Masatoshi

doi:10.1111/echo.14573

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MV orifice area ≤4.0 cm² is an important predictor of mitral stenosis after MitraClip implantation and is associated with poor outcomes [ 21 ]. Clip embolization can happen and clips have been reported being found in the right axillary artery in one case [ 22 ] and stuck to the LV apex in another [ 23 ].…”

Section: Reviewmentioning

confidence: 99%

Advancements in MitraClip Intervention for Mitral Regurgitation: A Comprehensive Review and Comparative Analysis of Clinical Trials

Shrivastava,

Allu

et al. 2024

Cureus

View full text Add to dashboard Cite

This comprehensive review explores the evolution and clinical impact of MitraClip intervention in the management of mitral regurgitation. Mitral regurgitation results from dysfunction in the mitral valve (MV) apparatus. The MitraClip Clip Delivery System was approved by the Food and Drug Administration (FDA) in 2013. The discussion delves into the procedural foundation of MitraClip intervention, primarily based on Alfieri’s technique of edge-to-edge leaflet approximation. As highlighted by key clinical trials, including Endovascular Valve Edge-to-Edge Repair (EVEREST) II Trial, Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial, and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation (MITRA-FR) trial, the efficacy and safety of MitraClip were evaluated in comparison to surgical interventions and guideline-directed medical therapy. Notably, the COAPT demonstrated significant benefits in reducing all-cause mortality and heart failure hospitalization, while the MITRA-FR presented contrasting results, emphasizing the importance of patient selection. An analysis of the EVEREST II trial underscores MitraClip's potential to achieve comparable outcomes to surgical intervention, emphasizing its role in reducing mitral regurgitation and improving clinical status. However, limitations and complications, such as device-related issues and the potential impact on future MV surgery, are discussed. The study also explores the evolving landscape of MV interventions, reflecting advancements and the growing acceptance of MitraClip. In conclusion, the MitraClip device represents a significant advancement in the treatment of mitral regurgitation. The data presented highlights its promising results in terms of reduced hospitalization rates, improved in-hospital mortality, and enhanced quality of life for patients. However, challenges remain, and careful consideration of patient selection and underlying pathology is crucial in determining the optimal treatment approach. Ongoing research and clinical experience will continue to refine our understanding of MitraClip's role in the evolving landscape of MV interventions.

show abstract

Section: Reviewmentioning

confidence: 99%

Advancements in MitraClip Intervention for Mitral Regurgitation: A Comprehensive Review and Comparative Analysis of Clinical Trials

Shrivastava,

Allu

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…In the rare case reports, one clip embolized in the right axillar artery without any symptoms and required no further treatment [ 73 ]. Another clip was localized in the renal artery and one clip, detached due to endocarditis, stuck in the apex of the left ventricle without a possibility for surgical removal [ 62 , 74 ].…”

Section: Complicationsmentioning

confidence: 99%

Complications Following MitraClip Implantation

et al. 2021

View full text Add to dashboard Cite

Purpose of Review To provide a detailed overview of complications associated with MitraClip therapy and its development over time with the aim to alert physicians for early recognition of complications and to offer treatment strategies for each complication, if possible. Recent Findings The MitraClip system (MC) is the leading transcatheter technique to treat mitral regurgitation (MR) and has been established as a safe procedure with very low adverse event rates compared to mitral surgery at intermediate to high risk or in secondary MR. Lately, the fourth MC generation has been launched with novel technical features to facilitate device handling, decrease complication rates, and allow the treatment of even complex lesions. Summary Although the complication rate is low, adverse events are associated with increased morbidity and mortality. The most common complications are bleeding, acute kidney failure, procedure-induced mitral stenosis, and an iatrogenic atrial septal defect with unknown clinical impact.

show abstract

Endocardite infectieuse sur prothèse après implantation de Mitra-Clip — Cas d’un succès du traitement médical sur une endocardite à Staphylococcus epidermidis et revue de littérature

Perier

Goursot

Russel

et al. 2020

Annales de Cardiologie et d'Angéiologie

View full text Add to dashboard Cite

Attachment of a migrated MitraClip to the left ventricular apex: A novel case report

Cited by 3 publications

References 8 publications

Advancements in MitraClip Intervention for Mitral Regurgitation: A Comprehensive Review and Comparative Analysis of Clinical Trials

Advancements in MitraClip Intervention for Mitral Regurgitation: A Comprehensive Review and Comparative Analysis of Clinical Trials

Complications Following MitraClip Implantation

Endocardite infectieuse sur prothèse après implantation de Mitra-Clip — Cas d’un succès du traitement médical sur une endocardite à Staphylococcus epidermidis et revue de littérature

Contact Info

Product

Resources

About